SARS-CoV-2 Initiates Programmed Cell Death in Platelets
Abstract
Coronavirus disease 2019 (COVID-19) is characterized by increased incidence of microthrombosis with hyperactive platelets sporadically containing viral RNA. It is unclear if SARS-CoV-2 (severe acute respiratory syndrome, corona virus-2) directly alters platelet activation or if these changes are a reaction to infection-mediated global inflammatory alterations. Importantly, the direct effect of SARS-CoV-2 on platelets has yet to be studied.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 03, 2021
- Source ID
- 10.1161/circresaha.121.319117
Entities
People
- Alyssa Cousineau
- Heather A. Corkrey
- Jane E. Freedman
- Jeffrey Rade
- Jennifer P Wang
- Kahraman Tanriverdi
- Krishna Mohan Parsi
- Matthew Godwin
- Milka Koupenova
- Mohan Somasundaran
- Olga Vitseva
- Ping Liu
- René Maehr
- Robert W. Finberg
- Rohan Bhandari
- Scott J. Cameron
- Shaukat Soofi
Organizations
- American Heart Association
- Case Western Reserve University
- Cleveland Clinic
- National Heart, Lung, and Blood Institute
- National Institutes of Health
- United States Department of Defense
- University of Massachusetts Medical School